Bharat Biotech
Indian multinational biotechnology company and vaccine manufacturer
Bharat Biotech ▸ Facts ▸ Comments ▸ News ▸ Videos
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.
| 0 shares | ShareTweetSavePostSend |
You Might Like
Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: StudyBharat Biotech’s indigenously developed Covid-19 vaccine Covaxin was overall found to have “much lower” AEFI (adverse effects following immunisation) rates in adolescents with a favourable..IndiaTimes - Published | |
Over 30% Covaxin takers suffered from health issues after 1 year: ReportA study from BHU analyzing the lasting impacts of Bharat Biotech's Covaxin found nearly a third of recipients reported adverse events of special interest (AESI). Among 926 participants, viral upper..IndiaTimes - Published | |
'Safety first', says Bharat Biotech amid AstraZeneca rowIndiaTimes - Published | |
Bharat Biotech begins clinical trials of more effective TB vaccine in IndiaIndiaTimes - Published | |
All Covid strains given to Bharat Biotech for a universal jab: CentreIndian Council of Medical Research (ICMR) has transferred all existing strains of variants of concern of SARS-CoV-2 - virus that causes Covid-19 - to Bharat Biotech Ltd for developing a universal Covid..IndiaTimes - Published | |
Covovax for adults to reach metros in a week: SIISerum Institute of India’s CEO Adar Poonawalla told TOI on Friday that doses of Covovax — Covid booster shot for adults — would reach major cities in four to five days, while a Bharat Biotech..IndiaTimes - Published | |
Covid-19: Health Minister launches Bharat Biotech's first India-made nasal vaccine, all you need to knowThe first nasal Covid-19 vaccine developed in India by Bharat Biotech, iNCOVACC launches on the 74th Republic Day.DNA - Published | |
Centre launches Bharat Biotech's iNCOVACC, India's first nasal Covid vaccineOn the occasion of Republic Day, India got its first-ever intranasal vaccine iNCOVACC, which will be manufactured by Hyderabad-based Bharat Biotech.The vaccine, dubbed "game changer" by some experts,..IndiaTimes - Published | |
India gets first nasal Covid vaccine: How it can be the 'game changer'Centre on Thursday launched India's first nasal Covid-19 vaccine iNCOVACC. Bharat Biotech's Incovacc received government approval for use as a booster dose in the country-wide mass inouclation program...IndiaTimes - Published | |
Covid-19: Bharat Biotech's iNCOVACC nasal vaccine to hit markets from February; know prices, eligibilityBharat Biotech's iNCOVACC will be the country of India's first needleless booster shot which will be available in private hospitals.DNA - Published | |
First nasal vaccine for Covid-19, Bharat Biotech's iNCOVACC, to be launched on January 26Bharat Biotech will offer the intranasal vaccine for Rs 325 to the government and Rs 800 to private hospitals.DNA - Published | |
First Indian intranasal Covid vaccine to be launched on January 26Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella..IndiaTimes - Published | |
Ocugen-Bharat Biotech Covid vaccine Covaxin meets main goals in US trialOcugen Inc said on Monday the Covid-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States. The vaccine, sold under brand name..IndiaTimes - Published | Amid Covid BF.7 scare in India, know who is eligible to get Bharat Biotech nasal vaccine booster doseThe booster dose of the Bharat Biotech intranasal Covid vaccine is now available on the CoWIN platform and can be booked by eligible populations.DNA - Published |
Bharat Biotech's nasal vaccine at Rs 800 for private centres and Rs 325 for govt hospitalsBharat Biotech’s intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose in private markets and at Rs 325 per dose for procurement by central and state governments, the vaccine maker..IndiaTimes - Published | Covid 4th wave scare in India: Bharat Biotech reveals price of nasal vaccine, check how to book booster dose onlineBharat Biotech has revealed the price of its intranasal Covid vaccine amid 4th wave scares, and the booster dose of the same can been booked online.DNA - Published |
Bharat Biotech's nasal vaccine to be priced at Rs 800/dose in pvt markets, Rs 325/dose for governmentsBharat Biotech on Tuesday said that its intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose for the private markets and Rs 325 per dose for central and state governments. The company..IndiaTimes - Published | 'Bharat Biotech annonces price of nasal vaccine': Covid-19 key pointsIndiaTimes - Published |
Bharat Biotech's nasal Covid vaccine can be used as booster: RegulatorIndiaTimes - Published | World's first intranasal Covid vaccine from Bharat Biotech gets CDSCO approvaliNCOVACC: Bharat Biotech said that launch dates, pricing and availability will be announced in due course of time.DNA - Published |
Bharat Biotech's intranasal Covid-19 vaccine iNCOVACC gets CDSCO nod for heterologous booster dosesIndiaTimes - Published Also reported by •DNA | Bharat Biotech's Intranasal Covid-19 Booster gets DCGI nod for emergency useFor individuals 18 years of age and older, the DCGI has authorised the use of Bharat Biotech's five arms heterologous booster, ANI reported.DNA - Published |
Indian govt, Bharat Biotech rubbish reports of Covaxin development being rushed under political pressureIndiaTimes - Published | Bharat Biotech's Covid-19 nasal vaccine approved for restricted use in IndiaBharat Biotech's Covid-19 recombinant nasal vaccine has been approved by the Indian drug regulator, the country's health minister Mansukh Mandaviya tweeted on Tuesday.IndiaTimes - Published Also reported by •DNA |
Bharat Biotech submits intranasal vaccine data to drug regulator, says vax safe and immunogenicBharat Biotech International Limited (BBIL) on Monday said its intranasal Covid-19 vaccine BBV154 has proved to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials for..IndiaTimes - Published | Bharat Biotech expects regulator's nod for intranasal Covid-19 vaccine in AugustBharat Biotech, which is working on an intranasal Covid-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, chairman and managing director of the company,..IndiaTimes - Published |
Biological E's Corbevax, Bharat Biotech's Covaxin get NTAGI's nod for use children aged 5-12 yearsPrime Minister Narendra Modi emphasised that all eligible children get the Covid-19 vaccine as soon as possible via "special programmes" in schools.DNA - Published | Bharat Biotech's Covid-19 nasal vaccine phase III trials completedIn an exclusive interview with ANI, Dr Ella said, "We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay,..IndiaTimes - Published |
Covaxin safe for 2-18 age group: BB studyIt conducted phase II/III, open-label, and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in children and adolescents in the 2-18 years of age group between..IndiaTimes - Published | Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR studyThe protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a..IndiaTimes - Published |
FDA lifts hold on Covaxin's clinical trials in USThe US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued by..IndiaTimes - Published | Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical holdThe US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin that were being conducted in..IndiaTimes - Published |
CEPI partners consortium of Bharat Biotech, Sydney University & ExcellGene to develop variant-proof SARS-CoV-2 vaccineIndiaTimes - Published | Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-oldBharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI...IndiaTimes - Published |
MEA asked Bharat Biotech to act on WHO suspension? Officials refute claimIndiaTimes - Published | Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEAWeeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world..IndiaTimes - Published |
DCGI gives approval for Bharat Biotech's Covaxin for children aged 6-12The Drug Controller General of India (DCGI) has given a restricted emergency use approval for Bharat Biotech's Covid-19 vaccine, Covaxin, for children between the age of six and 12. A Subject Expert..IndiaTimes - Published Also reported by •DNA | DCGI grants approval to Corbevax for kids aged 5-12, Covaxin for 6-12 age groupThe Drug Controller General of India (DCGI) on Tuesday granted emergency use approval to Covid-19 vaccines, Covaxin and Corbevax, for children below 12. Bharat Biotech's Covaxin has got nod for use in..IndiaTimes - Published |
Bharat Biotech asked to provide more data on Covid-19 vaccine Covaxin for children aged below 12The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin, for administering it to children aged..IndiaTimes - Published | Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on holdThe US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA. Bharat Biotech's partner for US and Canada for Covaxin, the FDA's..IndiaTimes - Published |
Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shotIndiaTimes - Published | Covishield, Covaxin prices slashed ahead of booster drive expansionSerum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..IndiaTimes - Published |
Japan recognises Covaxin to facilitate travel from April 10: Bharat BiotechIndiaTimes - Published | 'Amid drop in demand, Bharat Biotech slowed Covaxin production since February'IndiaTimes - Published |
No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat BiotechWith WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and..IndiaTimes - Published | SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age groupCovovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax.DNA - Published |
WHO suspends Covaxin supply for UN procurement citing GMP deficiencies at Bharat Biotech facilitiesIndiaTimes - Published | Will Covid-19 nasal vaccine prove effective against infection? AIIMS expert says THISAIIMS expert Dr Sanjay Rai talked about the effectiveness of the Bharat Biotech nasal vaccine against the Covid-19 infection.DNA - Published |
Covaxin showed better antibody response in 2-18 year olds than adults: Bharat BiotechIndiaTimes - Published | 'Precautionary dose' for 60+ with comorbidities 9 months after 2nd dose - Check new guidelinesBharat Biotech's Covaxin has been granted approval for restricted use in an emergency situation in the age group between 12 and 18 years.DNA - Published |
